logo-loader
viewReNeuron Group PLC

ReNeuron's retinal treatment 'appears to have sustained long-term beneficial effect'

ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott soon after the firm announced that its cell therapy for a degenerative eye disease held onto sight improvements for as long as a year after treatment.

The 12-month data reveal that people receiving surgery and the ReNeuron therapy could read seven more letters on a standard eye chart than those receiving surgery alone.

Quick facts: ReNeuron Group PLC

Price: 105 GBX

LSE:RENE
Market: LSE
Market Cap: £33.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: European airlines hammered over coronavirus outbreak

Headlines from the Proactive UK newsroom. Coronavirus is causing chaos among European airlines this morning. Wizzair (LON:WIZZ), easyJet (LON:EZJ) and Jet2 owner Dart Group (LON:DTG) are all down by up to 8-10% following the major outbreak in Italy at the weekend. ReNeuron (LON:RENE) has...

on 24/2/20

2 min read